Document is current
Any future updates will be listed below
-
Authors
Coupland, Lucy A.
Rabbolini, David J.
Schoenecker, Jonathan G.
Crispin, Philip J.
Miller, Jennene J.
Ghent, Tony
Medcalf, Robert L.
Aneman, Anders E.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05540834 at ClinicalTrials.govDocuments that mention this clinical trial
Point-of-care diagnosis and monitoring of fibrinolysis resistance in the critically ill: results from a feasibility study
https://doi.org/10.1186/s13054-023-04329-5
-
Funding
Funding for this research was provided by:
NIH (R01GM126062-01A1)
- License Information
-
More Information
Article History
Received: 31 October 2022
Accepted: 22 January 2023
First Online: 10 February 2023
Declarations
:
: All research was approved by the Southwestern Sydney Local Health District Human Research Ethics Committee (2021/ETH11630) and conducted in a large tertiary centre, Liverpool Hospital, Sydney, Australia, between December 2021 and August 2022. The ex vivo VET experiments were aligned with standard of care and trial eligibility screening; thus, consent was not required. Written informed consent was obtained from relatives for the patient entered onto the VETtiPAT-ARF study.
: Patient was consented to a clinical trial which included the publication of de-identified data.
: T. Ghent acts as a scientific consultant for Haemoview Diagnostics, Australia. The remaining authors have no conflicts of interest to declare.
